Basiliximab biobetter - Mabtech/Sorrento

Drug Profile

Basiliximab biobetter - Mabtech/Sorrento

Alternative Names: STI-003

Latest Information Update: 13 Aug 2015

Price : $50

At a glance

  • Originator Mabtech
  • Developer Mabtech Limited
  • Class Biobetters; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Interleukin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Autoimmune disorders

Most Recent Events

  • 03 Aug 2015 Phase-III clinical trials in Autoimmune disorders in China before August 2015 (unspecified route)
  • 03 Aug 2015 Mabtech announces intention to submit NDA to Chinese FDA
  • 03 Aug 2015 Monoclonal antibody biobetter licensed to Sorrento Therapeutics in European Union, Japan and North America
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top